BRAF and colorectal neoplasm: These data are extremely relevant in the perspective to design new therapeutic strategies and novel combination therapies of different molecular targeted agents in human BRAF-driven CRCs, a subset of colorectal tumors with poor prognosis [26–28] and low response to standard therapies and EGFR monoclonals [9–11].